MedTrace Logo

Environment, Inflammation and Metabolic Diseases Study

NCT07512609 · Status: RECRUITING · Type: OBSERVATIONAL · Enrollment: 8000

Last updated 2026-04-06

No results posted yet for this study

Summary

The aim is to establish an effective and practical early warning model for endocrine and metabolic diseases based on an environmental-gene-protein panoramic network, to uncover new mechanisms underlying the onset and progression of these diseases, and to screen for novel therapeutic targets.

Conditions

Interventions

OTHER

observe

A single observational cohort of study participants undergoing baseline biochemical screening for autonomous aldosterone secretion (AAS). No experimental interventions or treatments are administered. All participants receive standard clinical care and undergo standardized baseline assessments, including measurement of plasma aldosterone concentration (PAC) and plasma renin concentration (PRC) for AAS classification, as well as collection of demographic, clinical, biochemical, anthropometric data and biospecimens for proteomic analysis.

Sponsors & Collaborators

  • Qifu Li

    lead OTHER

Principal Investigators

  • Qifu Li, MD, PhD, Chief Physician · First Affiliated Hospital of Chongqing Medical University

Eligibility

Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2020-12-25
Primary Completion
2026-12-31
Completion
2026-12-31

Countries

  • China

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07512609 on ClinicalTrials.gov